title: The P2 receptor antagonist PPADS supports recovery from experimental stroke in vivo.
abstract: BACKGROUND
  After ischemia of the CNS, extracellular adenosine 5'-triphosphate (ATP) can reach high concentrations due to cell damage and subsequent increase of membrane permeability. ATP may cause cellular degeneration and death, mediated by P2X and P2Y receptors.
  
  
  RESULTS
  The effects of inhibition of P2 receptors by pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) on electrophysiological, functional and morphological alterations in an ischemia model with permanent middle cerebral artery occlusion (MCAO) were investigated up to day 28. Spontaneously hypertensive rats received PPADS or vehicle intracerebroventricularly 15 minutes prior MCAO for up to 7 days. The functional recovery monitored by qEEG was improved by PPADS indicated by an accelerated recovery of ischemia-induced qEEG changes in the delta and alpha frequency bands along with a faster and sustained recovery of motor impairments. Whereas the functional improvements by PPADS were persistent at day 28, the infarct volume measured by magnetic resonance imaging and the amount of TUNEL-positive cells were significantly reduced by PPADS only until day 7. Further, by immunohistochemistry and confocal laser scanning microscopy, we identified both neurons and astrocytes as TUNEL-positive after MCAO.
  
  
  CONCLUSIONS
  The persistent beneficial effect of PPADS on the functional parameters without differences in the late (day 28) infarct size and apoptosis suggests that the early inhibition of P2 receptors might be favourable for the maintenance or early reconstruction of neuronal connectivity in the periinfarct area after ischemic incidents.
authors: Department of Neurology, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
authors: Alexandra B
authors: AB
authors: Lämmer
authors: Alexander
authors: A
authors: Beck
authors: Benjamin
authors: B
authors: Grummich
authors: Annette
authors: A
authors: Förschler
authors: Thomas
authors: T
authors: Krügel
authors: Thomas
authors: T
authors: Kahn
authors: Dietmar
authors: D
authors: Schneider
authors: Peter
authors: P
authors: Illes
authors: Heike
authors: H
authors: Franke
authors: Ute
authors: U
authors: Krügel
references: J Biol Chem. 2009 Sep 18;284(38):25813-22
references: 19546214
references: Exp Brain Res. 2002 Dec;147(3):353-9
references: 12428143
references: Stroke. 2006 Mar;37(3):852-8
references: 16439696
references: Artif Organs. 2006 Oct;30(10):756-63
references: 17026574
references: Trends Neurosci. 2009 Feb;32(2):79-87
references: 19135728
references: Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):340-50
references: 11111828
references: Exp Cell Res. 2004 Oct 15;300(1):149-58
references: 15383322
references: Cell Calcium. 2010 Feb;47(2):122-9
references: 20167368
references: Brain Res Mol Brain Res. 2001 Oct 19;94(1-2):25-34
references: 11597762
references: Neuroscience. 2003;120(1):85-98
references: 12849743
references: Folia Neuropathol. 2009;47(3):213-27
references: 19813140
references: Neuroreport. 2002 Sep 16;13(13):1611-5
references: 12352612
references: J Med Chem. 1998 Jun 18;41(13):2201-6
references: 9632352
references: Neuroscience. 2004;127(2):431-41
references: 15262333
references: Science. 1982 Aug 27;217(4562):855-7
references: 7100929
references: Neurochem Int. 2005 Nov;47(6):442-8
references: 16029911
references: Glia. 2006 Nov 15;54(7):738-46
references: 17006902
references: Cell Mol Neurobiol. 2006 Oct-Nov;26(7-8):1057-83
references: 16710759
references: Clin Neurophysiol. 2006 Oct;117(10):2338-9
references: 16926108
references: J Neurochem. 2000 Sep;75(3):965-72
references: 10936177
references: J Neurotrauma. 1994 Apr;11(2):187-96
references: 7932797
references: Synapse. 2003 Feb;47(2):134-42
references: 12454951
references: Biochim Biophys Acta. 2010 Jan;1802(1):80-91
references: 19751827
references: J Cereb Blood Flow Metab. 2003 Mar;23(3):381-4
references: 12621313
references: Curr Med Chem. 2007;14(23):2429-55
references: 17979698
references: J Cereb Blood Flow Metab. 1988 Aug;8(4):474-85
references: 3392112
references: Int J Dev Neurosci. 2006 Apr-May;24(2-3):123-32
references: 16387466
references: J Neurosci. 2007 May 2;27(18):4957-68
references: 17475804
references: Stroke. 2009 Mar;40(3 Suppl):S111-4
references: 19064810
references: J Neurophysiol. 2006 Mar;95(3):1537-44
references: 16354727
references: Neuropathol Appl Neurobiol. 2001 Dec;27(6):481-95
references: 11903931
references: Curr Top Med Chem. 2011;11(8):973-1011
references: 21401499
references: Pharmacol Rev. 1998 Sep;50(3):413-92
references: 9755289
references: Eur J Pharmacol. 2002 Jul 5;447(2-3):261-9
references: 12151017
references: Brain Res Mol Brain Res. 2004 Sep 10;128(1):30-8
references: 15337315
references: J Neurosci. 2003 Mar 15;23(6):2348-56
references: 12657694
references: J Neurosci. 2004 Jan 7;24(1):1-7
references: 14715932
references: Arch Physiol Biochem. 1998 Dec;106(5):384-91
references: 10441060
references: Physiol Behav. 2003 Nov;80(2-3):167-75
references: 14637213
references: Recent Pat CNS Drug Discov. 2010 Jan;5(1):35-45
references: 19705995
references: Nat Rev Neurosci. 2009 Dec;10(12):861-72
references: 19888284
references: J Cereb Blood Flow Metab. 2003 Dec;23(12):1383-402
references: 14663334
references: J Cereb Blood Flow Metab. 2006 Jul;26(7):974-82
references: 16395292
references: Nat Med. 2004 Aug;10(8):821-7
references: 15258577
references: J Immunol. 1997 Aug 1;159(3):1451-8
references: 9233643
references: Brain Res. 1999 Mar 27;823(1-2):183-90
references: 10095025
references: Muscle Nerve. 2004 Feb;29(2):234-42
references: 14755488
references: Stroke. 1993 Apr;24(4):609-13
references: 8465371
references: Curr Pharm Des. 2008;14(33):3565-73
references: 19075733
references: Curr Top Med Chem. 2009;9(14):1240-60
references: 19849665
references: Glia. 2009 Aug 1;57(10):1031-45
references: 19115395
references: Curr Opin Investig Drugs. 2009 Jul;10(7):644-54
references: 19579170
references: J Neurosci. 1998 Jul 1;18(13):4891-900
references: 9634555
references: J Immunol. 2003 Jun 1;170(11):5728-38
references: 12759456
references: Int J Dev Neurosci. 2004 Nov;22(7):565-70
references: 15465287
references: Neurology. 1987 Jul;37(7):1153-9
references: 3601079
references: Trends Neurosci. 2009 Jan;32(1):19-29
references: 19008000
references: Purinergic Signal. 2007 Sep;3(4):435-45
references: 18404456
references: Pharmacol Ther. 2006 Jun;110(3):415-32
references: 16257449
references: Stroke. 2009 Dec;40(12):3864-8
references: 19797186
references: J Neuropathol Exp Neurol. 2004 Jul;63(7):686-99
references: 15290894
references: J Neurol Sci. 2000 Mar 15;174(2):141-6
references: 10727700
references: Neurosci Biobehav Rev. 1992 Summer;16(2):219-33
references: 1630732
references: Eur J Neurosci. 2006 May;23(10):2824-8
references: 16817887
references: Science. 1996 May 3;272(5262):735-8
references: 8614837
references: Eur J Pharmacol. 2001 May 25;420(2-3):R3-4
references: 11408042
references: Clin Neurophysiol. 2007 Nov;118(11):2525-32
references: 17889600